[HTML][HTML] Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
Immune checkpoint inhibitors show remarkable antitumor activity across multiple tumor
types, with approval of programmed death–1 (PD-1) inhibitors for non–small cell lung cancer …
types, with approval of programmed death–1 (PD-1) inhibitors for non–small cell lung cancer …
[HTML][HTML] Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
KC Suozzi, M Stahl, CJ Ko, A Chiang… - JAAD Case …, 2016 - jaadcasereports.org
CTLA-4 inhibition (ipilimumab) potentiates early T-cell activation during antigen
presentation. PD-1 inhibition (nivolumab) acts primarily on T cells that have already been …
presentation. PD-1 inhibition (nivolumab) acts primarily on T cells that have already been …
[HTML][HTML] Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
KC Suozzi, M Stahl, CJ Ko, A Chiang… - JAAD Case …, 2016 - ncbi.nlm.nih.gov
CTLA-4 inhibition (ipilimumab) potentiates early T-cell activation during antigen
presentation. PD-1 inhibition (nivolumab) acts primarily on T cells that have already been …
presentation. PD-1 inhibition (nivolumab) acts primarily on T cells that have already been …
[引用][C] Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
KC Suozzi, M Stahl, CJ Ko, A Chiang, SN Gettinger… - JAAD Case …, 2016 - cir.nii.ac.jp
Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データをさがす 大学 …
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データをさがす 大学 …
[引用][C] Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
KC Suozzi, M Stahl, CJ Ko, A Chiang, SN Gettinger… - JAAD Case …, 2016 - infona.pl
Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy ×
Close The Infona portal uses cookies, ie strings of text saved by a browser on the user's …
Close The Infona portal uses cookies, ie strings of text saved by a browser on the user's …
[PDF][PDF] Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
KC Suozzi, M Stahl, CJ Ko, A Chiang - 2016 - academia.edu
CTLA-4 inhibition (ipilimumab) potentiates early T-cell activation during antigen
presentation. PD-1 inhibition (nivolumab) acts primarily on T cells that have already been …
presentation. PD-1 inhibition (nivolumab) acts primarily on T cells that have already been …
[引用][C] Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
KC Suozzi, M Stahl, CJ Ko, A Chiang… - JAAD case …, 2016 - pubmed.ncbi.nlm.nih.gov
Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy JAAD …
Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy JAAD …
[PDF][PDF] Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
KC Suozzi, M Stahl, CJ Ko, A Chiang, SN Gettinger… - 2016 - cyberleninka.org
CTLA-4 inhibition (ipilimumab) potentiates early T-cell activation during antigen
presentation. PD-1 inhibition (nivolumab) acts primarily on T cells that have already been …
presentation. PD-1 inhibition (nivolumab) acts primarily on T cells that have already been …
Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy.
KC Suozzi, M Stahl, CJ Ko, A Chiang… - JAAD Case …, 2016 - europepmc.org
CTLA-4 inhibition (ipilimumab) potentiates early T-cell activation during antigen
presentation. PD-1 inhibition (nivolumab) acts primarily on T cells that have already been …
presentation. PD-1 inhibition (nivolumab) acts primarily on T cells that have already been …